Larry W. Buie
YOU?
Author Swipe
View article: Hematology‐oncology pharmacists: We hear you, we see you, we support you
Hematology‐oncology pharmacists: We hear you, we see you, we support you Open
Peer Reviewed
View article: Improving outcomes and mitigating costs associated with CAR T-cell therapy
Improving outcomes and mitigating costs associated with CAR T-cell therapy Open
Since the historic approval of tisagenlecleucel for the treatment of B-cell acute lymphoblastic leukemia in 2017, chimeric antigen receptor (CAR) T-cell therapies have altered the treatment paradigm for hematologic malignancies. Five CAR T…
View article: BENDAMUSTINE, RITUXIMAB, AND POLATUZUMAB VEDOTIN FOR RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA: SINGLE‐CENTER REAL‐WORLD EXPERIENCE
BENDAMUSTINE, RITUXIMAB, AND POLATUZUMAB VEDOTIN FOR RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA: SINGLE‐CENTER REAL‐WORLD EXPERIENCE Open
Introduction: In a pivotal phase 2 randomized cohort, addition of polatuzumab vedotin (pola) to bendamustine and rituximab (BR) improved rate of complete response (CR), progression-free survival (PFS), and overall survival (OS) versus BR a…
View article: Outpatient clinical pharmacy practice in the face of COVID-19 at a cancer center in New York City
Outpatient clinical pharmacy practice in the face of COVID-19 at a cancer center in New York City Open
Purpose With the rapid spread of COVID-19 in New York City since early March 2020, innovative measures were needed for clinical pharmacy specialists to provide direct clinical care safely to cancer patients. Allocating the workforce was ne…
View article: A phase I evaluation of the combination of vinflunine and erlotinib in patients with refractory solid tumors
A phase I evaluation of the combination of vinflunine and erlotinib in patients with refractory solid tumors Open
Epidermal growth factor receptor (EGFR) inhibition may overcome chemotherapy resistance by inhibiting important anti-apoptotic signals that are constitutively activated by an overstimulated EGFR pathway.
View article: Phase I trial of vinflunine and pemetrexed in refractory solid tumors
Phase I trial of vinflunine and pemetrexed in refractory solid tumors Open
Vinflunine is a novel vinca alkaloid with promising single agent clinical activity. Pemetrexed has at least additive activity with other vincas. A phase I trial was undertaken to assess the safety of vinflunine and pemetrexed in patients w…
View article: A Study of Layered Learning in Oncology
A Study of Layered Learning in Oncology Open
Objective. To explore use of pharmacy learners as a means to expand pharmacy services in a layered learning practice model (LLPM), to examine whether an LLPM environment precludes achievement of knowledge-based learning objectives, and to …
View article: Comparison of Conditioning Regimens for Allogeneic Hematopoietic Cell Transplantation in Non-Hodgkin Lymphoma
Comparison of Conditioning Regimens for Allogeneic Hematopoietic Cell Transplantation in Non-Hodgkin Lymphoma Open
BackgroundAllogeneic hematopoietic cell transplantation (allo-HCT) allows for the possibility of cure in patients (pts) with Non-Hodgkin Lymphoma (NHL) as it provides an immunologic graft-versus-lymphoma effect. Non-relapse mortality (NRM)…
View article: Correlation of IL-6 secretion and hyponatremia with the use of CD19+ chimeric antigen receptor T-cells
Correlation of IL-6 secretion and hyponatremia with the use of CD19+ chimeric antigen receptor T-cells Open
Hyponatremia is common in patients who received CD19+ CAR T-cells. There is an inverse linear relationship between IL-6 levels and nadir Na (p = 0.001). Further studies will be needed to confirm a causative relationship between IL-6 levels…
View article: Immunophenotype and Response to Immunotherapy of <i>RET</i>-Rearranged Lung Cancers
Immunophenotype and Response to Immunotherapy of <i>RET</i>-Rearranged Lung Cancers Open
RET rearrangements are identified in 1% to 2% of non-small-cell lung cancers (NSCLCs).1,2 In patients with advanced, RET-rearranged lung cancers, systemic therapy can be highly active. We demonstrated previously that pemetrexed-based chemo…
View article: Busulfan/Melphalan/Fludarabine (Bu/Mel/Flu) Conditioning Versus Total Body Irradiation/Thiotepa/Cyclophosphamide (HFTBI/Thio/Cy) Based Conditioning in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Undergoing CD34-Selected T-Cell Depleted Allogeneic Stem Cell Transplantation (alloSCT)
Busulfan/Melphalan/Fludarabine (Bu/Mel/Flu) Conditioning Versus Total Body Irradiation/Thiotepa/Cyclophosphamide (HFTBI/Thio/Cy) Based Conditioning in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Undergoing CD34-Selected T-Cell Depleted Allogeneic Stem Cell Transplantation (alloSCT) Open
IntroductionIn patients with poor risk AML or MDS in first complete remission (CR1), alloSCT can be potentially curative. Comparison of the non-hematologic toxicities between total body irradiation (TBI)-based conditioning versus chemother…
View article: More Intensive Fludarabine/Busulfan (Flu/Bu) Conditioning Regimens Result in Similar Outcomes Without Adding Serious Toxicity When Compared to Fludarabine/Melphalan (Flu/Mel) in Patients Undergoing Allogeneic Hematopoietic Cell Transplant (Allo-HCT)
More Intensive Fludarabine/Busulfan (Flu/Bu) Conditioning Regimens Result in Similar Outcomes Without Adding Serious Toxicity When Compared to Fludarabine/Melphalan (Flu/Mel) in Patients Undergoing Allogeneic Hematopoietic Cell Transplant (Allo-HCT) Open
Background: Recent studies have shown lower incidences of non-relapse mortality (NRM), acute graft-versus-host disease (aGVHD), and toxicity with Flu/Bu using 2 days of busulfan, whereas Flu/Mel has been associated with longer overall (OS)…
View article: CMET-08. PROGNOSTIC FACTORS AND OUTCOMES OF PATIENTS WITH CENTRAL NERVOUS SYSTEM (CNS) METASTATIC ALK-REARRANGED NON-SMALL CELL LUNG CANCER (NSCLC)
CMET-08. PROGNOSTIC FACTORS AND OUTCOMES OF PATIENTS WITH CENTRAL NERVOUS SYSTEM (CNS) METASTATIC ALK-REARRANGED NON-SMALL CELL LUNG CANCER (NSCLC) Open
PURPOSE: ALK-rearrangement is present in 5% of NSCLC patients. Crizotinib has significantly prolonged progression-free survival (PFS); however, about 70% of patients who progress on crizotinib develop CNS metastases. Prognostic factors for…